Application 125377
- Type
- BLA
- Sponsor
- BRISTOL MYERS SQUIBB
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | YERVOY | IPILIMUMAB | INJECTABLE; INJECTION | 3MG | No | No |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2327 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-2328 | YERVOY | ipilimumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 82402 | SUPPL | 2025-06-02 |
| 82401 | SUPPL | 2025-06-02 |
| 82334 | SUPPL | 2025-05-28 |
| 82010 | SUPPL | 2025-04-25 |
| 81940 | SUPPL | 2025-04-21 |
| 81902 | SUPPL | 2025-04-09 |
| 81881 | SUPPL | 2025-04-08 |
| 81173 | SUPPL | 2025-02-07 |
| 80996 | SUPPL | 2025-02-05 |
| 73533 | SUPPL | 2023-02-17 |
| 73529 | SUPPL | 2023-02-16 |
| 72723 | SUPPL | 2022-11-28 |
| 72722 | SUPPL | 2022-11-27 |
| 72700 | SUPPL | 2022-11-25 |
| 71181 | SUPPL | 2022-05-31 |
| 71180 | SUPPL | 2022-05-31 |
| 71168 | SUPPL | 2022-05-31 |
| 71064 | SUPPL | 2022-05-12 |
| 71063 | SUPPL | 2022-05-12 |
| 71054 | SUPPL | 2022-05-12 |
| 70385 | SUPPL | 2022-03-03 |
| 70288 | SUPPL | 2022-02-28 |
| 70287 | SUPPL | 2022-02-28 |
| 70282 | SUPPL | 2022-02-28 |
| 70281 | SUPPL | 2022-02-28 |
| 69648 | SUPPL | 2021-12-20 |
| 67589 | SUPPL | 2021-05-25 |
| 67581 | SUPPL | 2021-05-24 |
| 67580 | SUPPL | 2021-05-24 |
| 65648 | SUPPL | 2020-12-21 |
| 65230 | SUPPL | 2020-11-16 |
| 65228 | SUPPL | 2020-11-16 |
| 65222 | SUPPL | 2020-11-16 |
| 64821 | SUPPL | 2020-10-05 |
| 64794 | SUPPL | 2020-10-02 |
| 64648 | SUPPL | 2020-09-22 |
| 64647 | SUPPL | 2020-09-22 |
| 64624 | SUPPL | 2020-09-21 |
| 64282 | SUPPL | 2020-08-14 |
| 64281 | SUPPL | 2020-08-14 |
| 64280 | SUPPL | 2020-08-14 |
| 63769 | SUPPL | 2020-07-01 |
| 63749 | SUPPL | 2020-06-30 |
| 63748 | SUPPL | 2020-06-30 |
| 63328 | SUPPL | 2020-05-29 |
| 63295 | SUPPL | 2020-05-26 |
| 63294 | SUPPL | 2020-05-26 |
| 63089 | SUPPL | 2020-05-19 |
| 63050 | SUPPL | 2020-05-15 |
| 62125 | SUPPL | 2020-03-11 |
| 62118 | SUPPL | 2020-03-11 |
| 62111 | SUPPL | 2020-03-11 |
| 60088 | SUPPL | 2019-09-23 |
| 60085 | SUPPL | 2019-09-23 |
| 58691 | SUPPL | 2019-05-14 |
| 58653 | SUPPL | 2019-05-13 |
| 54901 | SUPPL | 2018-07-16 |
| 54869 | SUPPL | 2018-07-11 |
| 53713 | SUPPL | 2018-04-17 |
| 53678 | SUPPL | 2018-04-16 |
| 52545 | SUPPL | 2018-02-09 |
| 52525 | SUPPL | 2018-02-09 |
| 50751 | SUPPL | 2017-12-18 |
| 50695 | SUPPL | 2017-12-14 |
| 50163 | SUPPL | 2017-10-24 |
| 50138 | SUPPL | 2017-10-23 |
| 49075 | SUPPL | 2017-07-25 |
| 49051 | SUPPL | 2017-07-25 |
| 51940 | SUPPL | 2017-07-20 |
| 51939 | SUPPL | 2017-07-20 |
| 47502 | SUPPL | 2017-03-08 |
| 18894 | SUPPL | 2016-04-19 |
| 9728 | SUPPL | 2015-10-30 |
| 9729 | SUPPL | 2015-08-19 |
| 39942 | SUPPL | 2015-08-18 |
| 18893 | SUPPL | 2015-03-24 |
| 9727 | SUPPL | 2015-03-20 |
| 9726 | SUPPL | 2013-12-09 |
| 39941 | SUPPL | 2013-12-06 |
| 31946 | SUPPL | 2013-05-28 |
| 39940 | SUPPL | 2013-05-23 |
| 31945 | SUPPL | 2012-10-30 |
| 18892 | SUPPL | 2012-10-30 |
| 9725 | SUPPL | 2012-02-23 |
| 24365 | ORIG | 2011-06-08 |
| 22805 | ORIG | 2011-05-16 |
| 9724 | ORIG | 2011-03-29 |
| 18891 | ORIG | 2011-03-25 |
| 51209 | SUPPL | 1900-01-01 |
| 51208 | SUPPL | 1900-01-01 |